📊 ELTX Key Takeaways
Is ELTX a Good Investment? Thesis Analysis
Elicio Therapeutics is a pre-revenue pharmaceutical company burning significant cash with negative operating margins of -37.7M against zero revenue, indicating the company has not yet achieved commercial viability. Despite maintaining adequate liquidity with $18.6M in cash, the company's cash burn rate of $37M annually threatens runway, and the high debt-to-equity ratio of 6.11x combined with negative interest coverage of -1047.6x signals severe financial distress.
Why Buy ELTX? Key Strengths
- Adequate current liquidity position with $18.6M in cash and 2.38x current ratio
- Improving net loss trend with net income improving 23.8% YoY suggesting operational efficiency gains
- Early-stage pharmaceutical development company with potential pipeline upside if clinical programs succeed
ELTX Investment Risks to Consider
- Zero revenue generation indicates no commercial products and complete dependence on cash reserves for survival
- Severe cash burn of $37M annually with only $18.6M in cash creates critical runway risk of approximately 6 months
- Debt-to-equity ratio of 6.11x and inability to cover interest (-1047.6x coverage) indicate financial distress and high default risk
- Stockholders' equity of only $1.6M versus $24.2M in liabilities shows the company is technically insolvent from a balance sheet perspective
Key Metrics to Watch
- Cash burn rate and runway remaining until depletion
- Clinical trial progress and regulatory milestones for pipeline candidates
- Ability to secure additional funding through capital raises or partnerships
- Operating expenses reduction and timeline to potential revenue generation
ELTX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.38x current ratio provides a solid financial cushion.
ELTX Profitability Ratios
ELTX vs Healthcare Sector
How Elicio Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ELTX Overvalued or Undervalued?
Based on fundamental analysis, Elicio Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ELTX Balance Sheet & Liquidity
ELTX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Elicio Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.25 indicates the company is currently unprofitable.
ELTX Growth Metrics (YoY)
ELTX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2023 | N/A | -$4.5M | $-0.15 |
| Q3 2022 | N/A | -$8.8M | $-0.30 |
| Q2 2022 | $540.0K | -$8.8M | $-0.30 |
| Q1 2022 | $371.0K | -$14.2M | $-0.48 |
| Q3 2021 | N/A | -$15.6M | $-0.53 |
| Q2 2021 | N/A | -$13.2M | $-0.58 |
| Q1 2021 | N/A | -$13.1M | $-0.91 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ELTX Capital Allocation
ELTX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Elicio Therapeutics, Inc. (CIK: 0001601485)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELTX
What is the AI rating for ELTX?
Elicio Therapeutics, Inc. (ELTX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELTX's key strengths?
Claude: Adequate current liquidity position with $18.6M in cash and 2.38x current ratio. Improving net loss trend with net income improving 23.8% YoY suggesting operational efficiency gains.
What are the risks of investing in ELTX?
Claude: Zero revenue generation indicates no commercial products and complete dependence on cash reserves for survival. Severe cash burn of $37M annually with only $18.6M in cash creates critical runway risk of approximately 6 months.
What is ELTX's revenue and growth?
Elicio Therapeutics, Inc. reported revenue of $0.0.
Does ELTX pay dividends?
Elicio Therapeutics, Inc. does not currently pay dividends.
Where can I find ELTX SEC filings?
Official SEC filings for Elicio Therapeutics, Inc. (CIK: 0001601485) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELTX's EPS?
Elicio Therapeutics, Inc. has a diluted EPS of $-2.58.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELTX a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Elicio Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ELTX stock overvalued or undervalued?
Valuation metrics for ELTX: ROE of -2,418.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ELTX stock in 2026?
Our dual AI analysis gives Elicio Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELTX's free cash flow?
Elicio Therapeutics, Inc.'s operating cash flow is $-37.0M, with capital expenditures of $16.0K.
How does ELTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -2,418.8% (avg: 15%), current ratio 2.38 (avg: 2).